Bli medlem
Bli medlem

Du är här

2021-12-20

Xbrane Biopharma moves to Nasdaq Stockholm Mid Cap segment

Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE), a leading biosimilar developer, has announced that the company’s shares will be moved to Nasdaq Stockholm’s Mid Cap segment on January 3rd, 2022.

The move from the Small Cap segment is a result of Nasdaq’s annual review of the average market values within the Nordic market segments. The Mid Cap segment includes companies with a share value between EUR 150 million and EUR 1 billion. The move was announced by Nasdaq Stockholm on December 20th, 2021. The company is now taking the step from the Small Cap to the Mid Cap segment after a strong price trend during the year.

Contacts


Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us


Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.3bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally four biosimilar candidates in its pipeline targeting € 24.3bn in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.
For more information, visit www.xbrane.com.

Attachments


Xbrane Biopharma moves to Nasdaq Stockholm Mid Cap segment

Författare MFN